SCHEMBL4292919

SCHEMBL4292919

Nc1nc2ccc(Oc3cccc([N+](=O)[O-])c3)cn2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
LTA4H P09960 1/20 0.43
PTGS2 P35354 1/20 0.43
MAPT P10636 4/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
LPAR3 Q9UBY5 1/20 0.42
TNK2 Q07912 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
TDP2 O95551 1/20 0.40
F10 P00742 1/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
LMNA P02545 3/20 0.38
HTT P42858 1/20 0.38
PKM P14618 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4286269 0.84 ALDH1A1 (0.45) ALDH1A1LTA4HPTGS2MAPTMEN1
SCHEMBL4291714 0.80 ALDH1A1 (0.48) ALDH1A1LTA4HPTGS2MAPTMEN1
SCHEMBL13639068 0.78 KDR (0.36) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL23422083 0.77 ALDH1A1 (0.42) ALDH1A1LTA4HPTGS2MAPTMEN1
SCHEMBL29715554 0.77 ALDH1A1 (0.42) ALDH1A1LTA4HPTGS2MAPTMEN1
SCHEMBL4282021 0.76 KDR (0.61) TDP2
SCHEMBL16280446 0.75 JAK2 (0.43) ALDH1A1MAPTMEN1KMT2ATNK2
SCHEMBL2858588 0.74 KDR (0.50)
SCHEMBL9158141 0.74 ALDH1A1 (0.67) ALDH1A1LTA4HPTGS2MAPTMEN1
SCHEMBL9356592 0.74 ALDH1A1 (0.67) ALDH1A1LTA4HPTGS2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162445-B1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-11-27 EP disclosed
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
WO-2008150015-A1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF NOX3, NOX5, ZYX ALDH1A1 2812/4885LTA4H 3401/4885PTGS2 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.